Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial

Background and Objective. The aim of this study was to compare the effect of autologous bone marrow-derived chondrocytes (ABMDCs) with pharmacological management of osteoarthritis of knee (OAK) and assess the benefit of the two in the improvement of pain relief, functional betterment, and quality of...

Full description

Saved in:
Bibliographic Details
Main Authors: Mir Sadat-Ali, Abdallah S. AlOmran, Sulaiman A. AlMousa, Hasan N. AlSayed, Khalid W. AlTabash, Mohammed Q. Azam, Tarek M. Hegazi, Sadananda Acharya
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Advances in Orthopedics
Online Access:http://dx.doi.org/10.1155/2021/2146722
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832547792727310336
author Mir Sadat-Ali
Abdallah S. AlOmran
Sulaiman A. AlMousa
Hasan N. AlSayed
Khalid W. AlTabash
Mohammed Q. Azam
Tarek M. Hegazi
Sadananda Acharya
author_facet Mir Sadat-Ali
Abdallah S. AlOmran
Sulaiman A. AlMousa
Hasan N. AlSayed
Khalid W. AlTabash
Mohammed Q. Azam
Tarek M. Hegazi
Sadananda Acharya
author_sort Mir Sadat-Ali
collection DOAJ
description Background and Objective. The aim of this study was to compare the effect of autologous bone marrow-derived chondrocytes (ABMDCs) with pharmacological management of osteoarthritis of knee (OAK) and assess the benefit of the two in the improvement of pain relief, functional betterment, and quality of life (QOL). Patients and Methods. A prospective, randomized study was undertaken in patients with OAK grades II and III of Kellgren–Lawrence grading (KLG) in two groups. Group I had 5 million of intra-articular ABMDC in the affected joint, and Group II continued the nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy as needed. Before the treatment, patients were meticulously examined and data were entered for age, sex, Body Mass Index (BMI), Visual Analogue Scale (VAS), Modified Knee Society Score-Short Form (MKSSSF), and QOL. Patients were followed up for 3, 12, and 24 months to assess efficacy, safety, and tolerability. To assess the cartilage regeneration of the damaged cartilage, magnetic resonance imaging (MRI) was used. Results. There were a total of 60 patients who were followed up. Three patients in Group II were removed from the analysis as they underwent total knee arthroplasty (TKA). A notably significant improvement was noticed in the ABMDC group on all scores of VAS and MKSSSF with P<0.0001. The control group continued to be dissatisfied with the treatment they were taking. Conclusions. This study reveals that a single injection of 5 million of ABMDC was efficient in reducing the symptoms, improving the functional score and betterment of QOL.
format Article
id doaj-art-96c435dec75649b7b607cc235c8bf402
institution Kabale University
issn 2090-3472
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Advances in Orthopedics
spelling doaj-art-96c435dec75649b7b607cc235c8bf4022025-02-03T06:43:23ZengWileyAdvances in Orthopedics2090-34722021-01-01202110.1155/2021/2146722Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled TrialMir Sadat-Ali0Abdallah S. AlOmran1Sulaiman A. AlMousa2Hasan N. AlSayed3Khalid W. AlTabash4Mohammed Q. Azam5Tarek M. Hegazi6Sadananda Acharya7Department of Orthopaedic SurgeryDepartment of Orthopaedic SurgeryDepartment of Orthopaedic SurgeryDepartment of Orthopaedic SurgeryDepartment of Orthopaedic SurgeryOrthopaedic SurgeryKing Fahd Hospital of the UniversityKing Fahd Hospital of the UniversityBackground and Objective. The aim of this study was to compare the effect of autologous bone marrow-derived chondrocytes (ABMDCs) with pharmacological management of osteoarthritis of knee (OAK) and assess the benefit of the two in the improvement of pain relief, functional betterment, and quality of life (QOL). Patients and Methods. A prospective, randomized study was undertaken in patients with OAK grades II and III of Kellgren–Lawrence grading (KLG) in two groups. Group I had 5 million of intra-articular ABMDC in the affected joint, and Group II continued the nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy as needed. Before the treatment, patients were meticulously examined and data were entered for age, sex, Body Mass Index (BMI), Visual Analogue Scale (VAS), Modified Knee Society Score-Short Form (MKSSSF), and QOL. Patients were followed up for 3, 12, and 24 months to assess efficacy, safety, and tolerability. To assess the cartilage regeneration of the damaged cartilage, magnetic resonance imaging (MRI) was used. Results. There were a total of 60 patients who were followed up. Three patients in Group II were removed from the analysis as they underwent total knee arthroplasty (TKA). A notably significant improvement was noticed in the ABMDC group on all scores of VAS and MKSSSF with P<0.0001. The control group continued to be dissatisfied with the treatment they were taking. Conclusions. This study reveals that a single injection of 5 million of ABMDC was efficient in reducing the symptoms, improving the functional score and betterment of QOL.http://dx.doi.org/10.1155/2021/2146722
spellingShingle Mir Sadat-Ali
Abdallah S. AlOmran
Sulaiman A. AlMousa
Hasan N. AlSayed
Khalid W. AlTabash
Mohammed Q. Azam
Tarek M. Hegazi
Sadananda Acharya
Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
Advances in Orthopedics
title Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_full Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_fullStr Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_full_unstemmed Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_short Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_sort autologous bone marrow derived chondrocytes for patients with knee osteoarthritis a randomized controlled trial
url http://dx.doi.org/10.1155/2021/2146722
work_keys_str_mv AT mirsadatali autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial
AT abdallahsalomran autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial
AT sulaimanaalmousa autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial
AT hasannalsayed autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial
AT khalidwaltabash autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial
AT mohammedqazam autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial
AT tarekmhegazi autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial
AT sadanandaacharya autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial